pharmaphorum3d
FDA rejection of Spero's tebipenem 'raises resistance threat'
The FDA delivered a blow to Spero's hopes of bringing the carbapenem to market in a complete response letter (CRL) delivered this week, which said another trial would be required to support approval.
EurekAlert!3d
Antimicrobial resistance in hypermucoviscous and non-hypermucoviscous Klebsiella pneumoniae: a systematic review and meta-analysis
Antimicrobial resistance has recently increased due to emerging carbapenem-resistant Klebsiella pneumoniae and extended-spectrum β-lactamase (ESBL)-producing strains of K. pneumoniae. Osaka ...
Hosted on MSN1mon
EU healthcare systems face growing threat from carbapenem-resistant Enterobacterales
Carbapenem-resistant Enterobacterales (CRE), including carbapenem-resistant Klebsiella pneumoniae and carbapenem-resistant Escherichia coli, pose a major risk to patients and healthcare systems in ...